JNCCN Study Highlights Gaps in Patient Supportive Services at U.S. Cancer Centers

New research in the July 2021 issue of JNCCN indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States. Researchers found 85.4% of centers offered mental health services but only 45.5% had chemical dependency services.

JNCCN: New Evidence on Need to Address Muscle Health among Patients with Cancer

Results of new study in JNCCN from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.

Unexpected Findings on Weight Loss and Breast Cancer from International Study in JNCCN

New research in the February 2021 issue of JNCCN examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.

New Research in JNCCN Highlights Dangerous Disparities for Life-Saving Cancer Screening

New research in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers.

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.

JNCCN: New Research Finds Low Bone Health Testing Rates after Prostate Cancer Treatment

New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low.

New Research in JNCCN Sheds Light on Multi-Organ Adverse Events from Immunotherapy

New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously.

JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy

New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.

JNCCN: Many Hospitalized People with Advanced Cancer Struggle with Important Daily Tasks

New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission.

JNCCN: Improving COVID-19 Safety for Cancer Patients and Healthcare Providers

NCCN Best Practices Committee publishes peer-reviewed feature in JNCCN presenting latest insights on how to keep oncology patients and healthcare workers safe during COVID-19 pandemic. Visit NCCN.org/covid-19 for continually-updated resources for patients, providers, and care systems.

JNCCN: How to Manage Cancer Care during COVID-19 Pandemic

Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network

Younger Cancer Survivors Far More Likely to Experience Food and Financial Insecurity than their Cancer-Free Peers, According to Researchers from American Cancer Society

New research from the American Cancer Society in the March 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that younger cancer survivors are more likely to experience significant financial strain for food, housing, and monthly bills after diagnosis.

Gaps in Cure Rate Appear Linked to Race and Insurance Status for a Common HPV-Related Cancer, According to New Research

Largest population-based analysis on factors that affect survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) find significant racial and socioeconomic disparities, according to new study in JNCCN-Journal of the National Comprehensive Cancer Network.

Researchers Surprised by High Levels of Alcohol Consumption among Cancer Survivors

New research JNCCN—Journal of the National Comprehensive Cancer Network, using data from NHIS to examine self-reported drinking habits among people reporting a cancer diagnosis, finds 56.5% were current drinkers, 34.9% exceeded moderate drinking levels, and 21% engaged in binge drinking.

New Research in JNCCN Offers Reassurance about Rarity of Recurrence for Early-Stage Breast Cancer after Breast-Conserving Surgery

New research in the November 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network from Dana-Farber Cancer Institute examines the implications of invasive breast cancer after breast-conserving treatment for ductal carcinoma in situ (aka DCIS, a form of non-invasive breast cancer) and which factors could impact overall survival.

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN

Study in JNCCN—Journal of the National Comprehensive Cancer Network, finds early dose reduction of adjuvant FEC-D chemotherapy negatively impacts overall survival rates for women with intermediate- or high-risk breast cancer.